title: Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial.
abstract: OBJECTIVE
  The long-term clinical performance of drug-eluting stents (DES) coated with biodegradable polymers is poorly known.
  
  
  RESULTS
  A total of 274 coronary patients were randomly allocated to paclitaxel-eluting stents, sirolimus-eluting stents, or bare metal stents (2:2:1 ratio). The two DES used the same biodegradable polymers and were identical except for the drug. At three years, the pooled DES population had similar rates of cardiac death or myocardial infarction (9.0% vs. 7.1; p=0.6), but lower risk of repeat interventions (10.0% vs. 29.9%; p<0.01) than controls with bare stents. The cumulative 3-year incidence of definite or probable stent thrombosis in the pooled DES group was 2.3% (first year: 1.8%; second year: 0.4%; third year: zero). There were no significant differences in outcomes between paclitaxel- and sirolimus-eluting stents.
  
  
  CONCLUSIONS
  The biodegradable-polymer coated DES releasing either paclitaxel or sirolimus were effective in reducing the 3-year rate of re-interventions.
authors.affiliation: Heart Institute (InCor), University of São Paulo Medical School (USP), São Paulo, Brazil. pedro.lemos@incor.usp.br
authors.forename: Pedro A
authors.initials: PA
authors.lastname: Lemos
authors.forename: Bruno
authors.initials: B
authors.lastname: Moulin
authors.forename: Marco A
authors.initials: MA
authors.lastname: Perin
authors.forename: Ludmilla A R R
authors.initials: LA
authors.lastname: Oliveira
authors.forename: J Airton
authors.initials: JA
authors.lastname: Arruda
authors.forename: Valter C
authors.initials: VC
authors.lastname: Lima
authors.forename: Antonio A G
authors.initials: AA
authors.lastname: Lima
authors.forename: Paulo R A
authors.initials: PR
authors.lastname: Caramori
authors.forename: Cesar R
authors.initials: CR
authors.lastname: Medeiros
authors.forename: Mauricio R
authors.initials: MR
authors.lastname: Barbosa
authors.forename: Fabio S
authors.initials: FS
authors.lastname: Brito
authors.forename: Expedito E
authors.initials: EE
authors.lastname: Ribeiro
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D017239:Paclitaxel / Q000008:administration & dosage; D011108:Polymers; D016016:Proportional Hazards Models; D011474:Prosthesis Design; D018570:Risk Assessment; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D011108:Polymers; D017239:Paclitaxel; D020123:Sirolimus